双边视神经病变与ALK阳性转移性肺腺癌的洛拉提尼布单疗法相关
Alan W Kong1, Alexander R Engelmann1, Mahdieh Hosseini2
1University of California Los Angeles, Stein Eye Institute, Department of Ophthalmology, Los Angeles, CA, USA.
American journal of ophthalmology case reports
|May 6, 2024
概括
洛拉提尼布是一种针对肺癌的向疗法,可导致视力损失由于视觉神经病变. 用皮质类固醇和等离子体酶迅速治疗导致患者的视力恢复.
科学领域:
- 在瘤学瘤学.
- 眼科医生 眼科 眼科
- 神经学 神经学
背景情况:
- 洛拉提尼布是一种第三代氨酸激酶抑制剂,向形淋巴瘤激酶 (ALK) 和ROS1重组.
- 转移性非小细胞肺癌 (NSCLC) 的治疗通常涉及ALK抑制剂.
- 双边视神经病变是一种罕见但严重的某些向治疗的潜在不良影响.
更多相关视频
06:03Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
Published on: January 19, 2019
17.0K
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.6K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.6K
02:57Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K